2,146 Shares in Celgene Co. (CELG) Acquired by Warren Averett Asset Management LLC

Warren Averett Asset Management LLC acquired a new stake in shares of Celgene Co. (NASDAQ:CELG) during the 1st quarter, HoldingsChannel.com reports. The fund acquired 2,146 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

Other hedge funds have also recently made changes to their positions in the company. Neuberger Berman Group LLC raised its position in shares of Celgene by 2.6% during the third quarter. Neuberger Berman Group LLC now owns 408,133 shares of the biopharmaceutical company’s stock worth $36,524,000 after acquiring an additional 10,316 shares during the last quarter. Morgan Stanley raised its position in shares of Celgene by 20.4% during the third quarter. Morgan Stanley now owns 3,236,323 shares of the biopharmaceutical company’s stock worth $289,620,000 after acquiring an additional 549,404 shares during the last quarter. BKD Wealth Advisors LLC raised its position in shares of Celgene by 18.6% during the fourth quarter. BKD Wealth Advisors LLC now owns 4,188 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 658 shares during the last quarter. Boston Advisors LLC raised its position in shares of Celgene by 166.5% during the fourth quarter. Boston Advisors LLC now owns 41,924 shares of the biopharmaceutical company’s stock worth $2,687,000 after acquiring an additional 26,194 shares during the last quarter. Finally, Norway Savings Bank raised its position in shares of Celgene by 8.4% during the fourth quarter. Norway Savings Bank now owns 3,490 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 270 shares during the last quarter. Hedge funds and other institutional investors own 71.71% of the company’s stock.

A number of equities research analysts have recently weighed in on CELG shares. Zacks Investment Research upgraded Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 target price for the company in a research report on Wednesday, January 23rd. Cowen started coverage on Celgene in a research report on Tuesday, February 26th. They set a “market perform” rating and a $102.00 target price for the company. Mizuho set a $103.00 target price on Celgene and gave the stock a “buy” rating in a research report on Friday, April 5th. William Blair downgraded Celgene from an “outperform” rating to a “market perform” rating in a research report on Monday, April 1st. Finally, ValuEngine upgraded Celgene from a “sell” rating to a “hold” rating in a research report on Saturday, March 30th. Twenty investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $95.96.

NASDAQ CELG opened at $95.42 on Friday. The stock has a market capitalization of $67.30 billion, a P/E ratio of 12.54, a P/E/G ratio of 0.44 and a beta of 1.68. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 2.42. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $97.07.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.10. The business had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.01 billion. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The firm’s revenue was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.05 earnings per share. On average, equities research analysts predict that Celgene Co. will post 9.85 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “2,146 Shares in Celgene Co. (CELG) Acquired by Warren Averett Asset Management LLC” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/19/2146-shares-in-celgene-co-celg-acquired-by-warren-averett-asset-management-llc.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: What is a put option?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.